Solely long-term application of Gefitinib (EGFR TKI) and Lapatinib (EGFR/Her2 TKI) induced an upregulation of PTPIP51/PTP1B interactions [50], thus, portraying a potential adaption mechanism of the cancer cell to the applied TKI treatment and not a direct effect of the TKI. The gene discussed is RMDN3; the disease is cancer.